FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Optimizing AAV Outcomes: Maintenance Therapies
Bernhard Hellmich, MD
Silke R. Brix, MD, MRCP, SCPR
Managing Patients With AAV in the Rheumatology Clinic
Andreas Kronbichler, MD
Elevating Care for Patients With Severe Renal Disease in AAV
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
Unmasking IgAN: From Suspicion to Timely Diagnosis
Jörg Latus, MD
Chee Kay Cheung, MBCHB, MRCP, PHD
Finally, I Can Take a Break from My Itch! Optimizing CKD-aP Treatment
Advances in IgAN Care From Kidney Week
Sydney Tang, MBBS, MD
Optimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
Jürgen Floege, PhD
Jonathan Barratt, PhD
Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management
David Wheeler, MB, CHB, MD, FRCP
Managing Symptom Clusters in Patients on Hemodialysis With CKD-aP
Kelly Chenlei Li, MBBS, FRACP
Paul Bennett, RN, MHSM, PhD, FISN
Thilo Krüger, MD, PhD
Improving CKD Patient Outcomes with SGLT2 Inhibitors
Gates B. Colbert, MD
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Achieving Success in IgAN & FSGS
Siân Griffin, MD, PhD
Loreto Gesualdo, MD, FERA
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Donald E. Kohan, MD, PhD
Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease
Mario Cozzolino, MD, PhD
Jan T. Kielstein, MD, FASN, FERA
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.